Work

Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

Year: 2010

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/0008-5472.sabcs10-s3-3

Authors: J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, C Aura, E De Azambuja, H Gomez, P Dinh, K Fauria, V Van Dooren, P Paoletti, A Goldhirsch, T-W Chang, I Lang, M Untch, RD Gelber, M Piccart-Gebhart

Institutions: Institut Jules Bordet, Dana-Farber Cancer Institute, Instituto Nacional de Enfermedades Neoplásicas, Vall d'Hebron Hospital Universitari, National Cheng Kung University Hospital

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1978434864

Cites:

Cited by: 117

Related to: 10